Gent, Belgium: September 30, 2015 - Fujirebio Europe today announced the release of its new Lumipulse G Pepsinogen I and Pepsinogen II assays which will be immediately available for testing on its CLEIA-based LUMIPULSE G systems, the LUMIPULSE G600II and the LUMIPULSE G1200.
Gent, Belgium: July 8, 2015 - Fujirebio Europe today announced the release of its new TENDIGO automate. The TENDIGO is a small, state-of-the-art, and cost-efficient instrument designed specifically for laboratories who seek to perform low throughput automation of Fujirebio’s gold standard strip-based INNO-LIA and INNO-LiPA assay portfolios. The instrument also allows for automated testing of other blot strips (open protocols).
Gent, Belgium: June 18, 2015 - Fujirebio Europe today announced the release of its new Lumipulse G HE4 assay which will be available for testing on its CLEIA-based LUMIPULSE G systems, the LUMIPULSE G600II and the LUMIPULSE G1200.
Gent, Belgium: March 5, 2015 - Fujirebio Europe today announced the release of the INNO-LiPA® HPV Genotyping Extra II assay for HPV type-specific patient monitoring and cervical cancer management. This CE-marked strip-based assay is available for automated testing on the Auto-LiPA™ 48 and AutoBlot 3000H platforms and the upcoming TENDIGO™ platform as well as for manual testing.
Gent, Belgium: October 1st 2014 - The LUMIPULSE G600II, a new member in the LUMIPULSE G series of chemiluminescent enzyme immunoassay (CLEIA) analyzers from Fujirebio, is now available on the European market. The LUMIPULSE G600 II is a compact and robust benchtop analyzer which features a constant throughput of 60 tests per hour.
Gent, Belgium: September 12 2014 - Fujirebio Europe today released a series of specialized assays for its chemiluminescent enzyme immunoassay (CLEIA) system, the LUMIPULSE® G1200, dedicated to the diagnosis and monitoring of HBV infection and the treatment of HBV patients. The HBV panel notably includes an entirely new tool in HBV testing, the Lumipulse® G HBcrAg, a unique serological marker (available as a Research Use Only test) correlated with cccDNA for improved monitoring of patients under treatment.
Gent, Belgium: April 4th 2014 - Fujirebio Europe today announced its intention to proceed with a reorganization in order to bring further focus and weight to the ongoing introduction of the LUMIPULSE® G1200 system on the European market, commenced in 2011. Fujirebio Europe has informed the Work’s Council in Gent about the estimated impact on employment and has communicated its intention to proceed for collective dismissal.
Fujirebio Europe announces the update of its entire range of INNOTEST® biomarkers for Alzheimer testing in routine. At the same occasion the company launches the INNOTEST® β-AMYLOID (1-40) test, an immunoassay kit for the quantification of β-Amyloid(1-40) in cerebrospinal fluid.